MENLO PARK, Calif.--(BUSINESS WIRE)--Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced that Francesco M. Marincola, M.D., chief scientific officer of Refuge, will present during the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting & Pre-Conference Programs (SITC 2019).
Dr. Marincola will deliver a scientific overview detailing Refuge’s platform technology during the Novel Multi-Targeted Therapeutic Platform program, held November 6 at the Gaylord National Hotel & Convention Center in Maryland. The overview will include recent data from Refuge’s proprietary receptor-dCas platform and its multi-functional therapeutic applications.
“The work being done at Refuge Biotechnologies builds upon the promise of CRISPR interference and CRISPR activation, and has demonstrated the ability to develop a novel therapy that induces gene modulation of multiple genes simultaneously without making permanent edits to the genome,” said Dr. Marincola. “This capability has the potential to be combined with numerous therapeutic mechanisms in a single customizable treatment. We look forward to sharing progress as we advance towards the clinic.”
Details of the presentation are as follows:
Title: Contextual reprogramming of T cells for multi-targeted therapeutics: checkpoint blockade, immune resilience, and stemness to overcome immune resistance and reduce toxicity, all in one cell product
Presenter: Francesco M. Marincola, M.D.
Date and Time: Wednesday, November 6, 2019 at 4:15 p.m. ET
Session 2: Novel Platforms and Innovation
About Refuge Biotechnologies
Refuge Biotechnologies is a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy. Refuge's proprietary receptor-dCas platform leverages a unique gene engineering approach based on precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). By connecting ligand specific receptors to dCas, Refuge enables cells to sense its surroundings and conditionally activate or repress multiple genes when they encounter specific external antigens. In particular, with receptor-dCas, immune cells can now be engineered to conditionally turn off certain genes, such as PD-1, to generate more potent CAR-T immune cells when it senses the presence of a tumor cell. For further information, please visit www.refugebiotech.com.